Radiopharm Theranostics

Contributing Author

Recent Articles by Radiopharm Theranostics

Apr-23	Radiopharm Theranostics Reports Business Update RADX GlobeNewswire
Apr-20	Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026 RADX GlobeNewswire
Apr-16	Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases RADX GlobeNewswire
Apr-08	Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial RADX GlobeNewswire
Apr-07	Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S. RADX GlobeNewswire
Mar-27	Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer RADX GlobeNewswire
Mar-24	Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases RADX -10.78% GlobeNewswire
Feb-24	Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01) RADX GlobeNewswire
Jan-28	Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates RADX GlobeNewswire
Jan-12	RAD Increases Ownership in Radiopharm Ventures to 87.5% RADX GlobeNewswire
Dec-15	Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases RADX +149.53% GlobeNewswire
Nov-18	Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer RADX GlobeNewswire
Nov-17	Radiopharm Theranostics Announces 50% Enrollment in Phase 2b Clinical Trial of RAD101 Imaging in Brain Metastases RADX GlobeNewswire
Nov-12	Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204 RADX GlobeNewswire
Oct-20	Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs RADX -19.83% GlobeNewswire
Oct-20	Radiopharm Theranostics completes A$35 million Placement and launches a A$5 million Share Purchase Plan RADX -19.83% GlobeNewswire
Oct-01	Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 'HEAT' Dose Escalation Clinical Trial RADX GlobeNewswire
Jul-29	Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update RADX GlobeNewswire
Jul-28	Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01) RADX GlobeNewswire
Jul-22	Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board RADX GlobeNewswire
Jun-24	Radiopharm Theranostics and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb Phase I Clinical Trial in Australia RADX +5.69% GlobeNewswire
Jun-11	Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases RADX -5.84% GlobeNewswire
Jun-04	Radiopharm Theranostics Doses First Patient in Phase 1 'HEAT' Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors RADX GlobeNewswire
Jun-02	Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake RADX +11.16% GlobeNewswire
May-19	ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177 RADX GlobeNewswire
May-12	Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC) RADX GlobeNewswire
May-07	Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference RADX GlobeNewswire

Radiopharm Theranostics

Recent Articles by Radiopharm Theranostics

Upgrade your Finviz experience